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Abstract: This report describes a case showing histologic features of acute cholangitis with 
an over-the-counter drug. A 48-year-old woman was diagnosed with general malaise and 
  progressive jaundice. A thorough review of her medical history revealed that the patient had taken 
an over-the-counter drug, Pabron Gold®, which she had used previously, that may have caused 
liver injury. Laboratory investigations revealed jaundice and liver dysfunction. Endoscopic 
retrograde cholangiography detected no extrahepatic biliary duct dilatation or stones. Liver 
biopsy indicated acute cholangitis involving neutrophils and eosinophils. Electron microscopy 
revealed fragmented nuclei, indicating that the degenerative bile duct-related epithelial cells 
were in an apoptotic process.
Keywords: liver injury, over-the-counter drug, histologic features, acute cholangitis, electron 
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Introduction
Drug-induced liver injury (DILI) is a rare condition. Reactions that result in DILI 
are regarded as idiosyncratic, occurring from therapeutic doses with a likelihood of 
occurrence in 1/1000 to 1/100,000 patients, with a pattern that is consistent for each 
drug and for each drug class. Idiosyncratic reactions are characterized by a variable 
delay or latency period of 5–90 days following initial ingestion of the drug. They are 
frequently fatal if the drug is taken continually, even after the onset of the reaction.1 In 
Japan, liver injury might be hepatocellular (59%), mixed (20%), or cholestatic (20%).2 
An examination of causal drugs during the periods 1997–2006 and 1989–1998 revealed 
antibiotics and antipyretic/analgesic/anti-inflammatory drugs to be among the top ranked 
in each period (14.3% and 9.9%, respectively, in 1997–2006), while dietary supplements 
and Chinese herbal medicines each showed an increase   during 1997–2006 (10.0% and 
7.1%, respectively), and over-the-counter drugs remained at similar levels during both 
periods (5.5% in 1997–2006 and 5.8% in 1989–1998).2 Repeated drug injections that 
have a broader spectrum of compounds and a personal history of previous reaction to 
a drug are common patterns among people with severe or prolonged liver injury.3–6
This report describes a case showing histologic features of acute cholangitis of 
cholestatic type associated with the over-the-counter drug Pabron Gold® (Taisho 
Pharmaceutical Co Ltd, Tokyo, Japan).
Case report
A 48-year-old woman was admitted to the authors hospital with progressive jaundice 
and general malaise. She had no history of significant illness, dietary or lifestyle International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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modification, or alcohol or drug use. She started to develop 
persistent epigastric distress and general malaise 4 days 
before admission. A thorough review of her medical   history 
showed that the patient had taken an over-the-counter 
drug, Pabron Gold (each tablet containing dihydrocodeine 
phosphate, 8 mg; di-methylephedrine hydrochloride, 20 mg; 
guaifenesin, 41.67 mg; acetaminophen, 300 mg; lysozyme 
hydrochloride, 20 mg; carbinoxamine maleate, 2.5 mg; anhy-
drous caffeine, 25 mg; bisibutiamine, 8 mg; and riboflavin, 
4 mg), for upper respiratory inflammation. She took three 
tablets each day December 20–23, 2010, then January 4–6, 
2011, and again January 21–23, 2011. She was admitted 
to the authors’ hospital on February 6, 2 weeks after the 
last dose.
Before presentation at a local hospital on February 5, 
she had noticed jaundice with subsequent darkened urine 
and lighter-colored stools. She was referred to the authors’ 
hospital for additional investigation of hyperbilirubinemia. 
On admission, physical examination showed severe muco-
cutaneous jaundice with a slightly distended abdomen. The 
liver was enlarged by 3 cm below the right coastal margin: 
firm, but not tender. She had no skin eruption or rash. 
Her body temperature was 36.6°C and her pulse rate was 
70 beats/min. Respiration was 12 breaths/min. Blood pressure 
was 117/80 mmHg. Her height and weight were 156.5 cm 
and 62.9 kg, respectively. Blood tests showed a white blood 
cell count of 5880/µl (neutrophils 67.4%, lymphocytes 
22.4%, monocytes 7.8%, eosinophils 7.8%). Her red blood 
cell count was 377 × 104/µl, with hemoglobin of 12.3 g/dL, 
platelets of 21.9 × 104/mm3, prothrombin time 100%, and 
C-reactive protein of 4.42 mg/d. Urinalysis results showed 
specific gravity 1.017 g/mL, pH 6.0, sugar (–), protein (–), 
ketone (1+), bilirubin (3+), and urobilinogen (+/–). Blood 
biochemical tests showed the following: total bilirubin 
6.7 mg/dL, direct bilirubin 5.2 mg/dL, aspartate aminotrans-
ferase 182 IU/L, alanine aminotransferase 376 IU/L, lactate 
dehydrogenase 282 IU/L, alkaline phosphatase 936 IU/L, 
γ-glutamyl transferase 772 IU/L, cholinesterase 377 U/mL, 
total protein 8.7 g/dL, albumin 4.5 g/dL, total cholesterol 
248 mg/dL, triglycerides 171 mg/dL, blood urea nitrogen 
8.3 mg/dL, creatinine 0.7 mg/dL, and pancreatic enzymes 
within normal limits. Viral hepatitis serology was performed. 
Results were negative for hepatitis A virus, hepatitis B virus, 
hepatitis C virus, Epstein–Barr virus, and Cytomegalovirus. 
Other relevant data were the   following: immunoglobulin 
(Ig) G 1907 mg/dL, IgG4 80.2 mg/dL, IgM 95 mg/dL, 
antinuclear autoantibody ×40 (normal range: below ×40), 
mitochondria M2 Ab, P-antineutrophil cytoplasmic antibody 
,3.5 (negative), C-antineutrophil cytoplasmic antibody ,1.3 
(negative), soluble interleukin 2 receptor 294 (normal range: 
145–466) U/mL, and ferritin 452 (normal range: 4.0–62) 
ng/dL (Table 1).
Ultrasonographic evaluation yielded no evidence of 
dilated intrahepatic or dilated extrahepatic biliary ducts. 
Computed tomography (axial image) revealed no mass lesion 
(Figure 1A). Endoscopic retrograde cholangiography (ERC) 
detected no stones and extrahepatic biliary duct dilatation 
(Figure 1B). Therefore, the impaired hepatic function was 
not caused by extrahepatic injury but by liver damage. Her 
recent use of Pabron Gold was suspected as the cause of the 
liver injury. A drug-induced lymphocyte stimulation test 
for Pabron Gold was negative. A needle liver biopsy was 
performed on the tenth hospital day. Histological examina-
tion showed the absence of fibrosis and regenerative nodules 
and the presence of spotty necrosis, inflammation, edema, 
bile canalicular cholestasis, and pigmented hepatocytes 
around the central vein (Figure 2A). The inflammatory 
infiltrate contained polynuclear neutrophils and a varying 
number of eosinophils. Interlobular bile duct destruction was 
observed in the portal tract (Figure 2B). Both hematoxyline-
eosine and diastase-digested periodic acid-Schiff showed 
intraepithelial neutrophilic infiltration in the interlobular bile 
duct (Figure 2C). Silver staining showed that the basement 
membrane of the bile duct was preserved, but the nuclear 
arrangement was irregular (Figure 2D). No evidence of 
portal fibrosis was found from Masson’s trichrome stain 
(Figure 2E).
Immunohistochemical cytokeratin (CK) 7 staining was 
also investigated in this case; minimal ductular reaction 
was visible (Figure 2F). Tissues histologically stained with 
reticulin stain were assessed using ImageJ (v 1.44p; National 
Institutes of Health, Bethesda, MD), a semiautomatic image 
analysis system. The profiles of the objects to be examined 
were traced on a digitizer board at x200 magnification. Then 
measurements were performed as described previously.7 The 
bile duct/hepatic artery volume ratio was 1.303 (n = 14). These 
findings were consistent with histologic features of acute 
cholangitis and cholestatic type associated with   drug-induced 
liver injury and without ductopenia.
Electron microscopy was performed to further investigate 
hepatocytic pigmentation and bile duct destruction. 
Deposition of electron-dense biliary substances together 
with condensed polymorphic and fragmented nuclei 
was observed, suggesting degenerative bile duct-related 
epithelial cell apoptotic processes (Figure 3A). Moreover, 
an electron micrograph showed a Canal of Hering partially International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Figure  1  Computed  tomography  (axial  image,  arterial  phase)  and  endoscopic 
retrograde  cholangiography  findings.  (A)  Computed  tomography  imaging  shows 
no mass lesion. (B) endoscopic retrograde cholangiography shows no stones in 
common bile duct and no extrahepatic biliary duct dilatation.
Table 1 Patient’s laboratory data
Blood count
WBC 5800 3300–9000/µl
  Neu 67.44%
  Lym 22.4%
  Mono 7.8%
  eo 7.8%
rBC 3.77 × 104 380–500 × 104/µl
Hb 12.3 11.5–15.0 g/dL
Plt 21.9 × 103 140–340 × 103/µl
Coagulation system
PTINr 1.12 0.85–1.15
Blood chemistry
T-bil 6.7 0.2–1.2 mg/dL
D-bil 5.2 0.0–0.2 mg/dL
AsT 182 10–40 IU/L
ALT 376 5–45 IU/L
LDH 282 120–240 IU/L
ALP 936 100–325 IU/L
γ-GTP 772 ,30 IU/L
Che 377 200–452 IU/L
TP 8.7 6.7–8.3 g/dL
ALB 4.5 3.8–5.3 g/dL
T-chol 248 120–219 mg/dL
TG 171 30–149 mg/dL
Na 140 137–147 meq/L
K 5.1 3.5–5.0 meq/L
CI 99 98–108 meq/L
CrP 4.42 ,0.3 mg/dL
GIc 97 70–109 mg/dL
TsH 0.821 0.436–3.8 µlU/mL
FT4 0.87 1.0–1.7 ng/dL
Thyroglobulin Ab 0.6 (+) ,0.3 U/mL
Serological examination
lgm-HAAb (-) ,0.80
HBsAg (-)
Igm-HBc Ab (-)
HCV Ab (-)
HCV rNA ,1.2 ,1.2 log lU/mL
eBV-VCA IgM ,10 , ×10
eBV-VCA IgG ×320 , ×10
eBV-eBNA ×1600 , ×10
IgM CMV (-) 0.8
IgMHeV (-)
IgG 1907 870–1700 mg/dL
IgG4 80.2 4.8–105.0 mg/dL
IgM 95 46–260 mg/dL
ANA ×40 , ×40
Mitochondria M2Ab ,5.0 (-) ,7.0
P-ANCA ,3.5 (-) ,3.5 U/mL
C-ANCA ,1.3 (-) ,9.0 U/mL
sIL-2r 294 124–466 U/mL
Feritin 452 4.0–62.2 ng/dL
DLST
Pablon 149 ,179%
HLA typing
A* 02:01:01 24:02:01
B* 40:02:01
(Continued)
Table 1 (Continued)
C* 03:04:01
DrB1* 11:01:01 14:01:01
DQB1* 03:01:01 05:03:01
DPB1* 02:01:02 02:02
DQA1* 01:04 05:05
Abbreviations: WBC, white blood cells; Neu, neutrophils; Lym, lymphocytes; Mono, 
monocytes; eo, eosinophils; rBC, red blood cells; Hb, hemoglobin; Plt, platelets; 
PTINr,  prothrombin  time  international  normalized  ratio;  T-bil,  total  bilirubin; 
D-bil, direct bilirubin; AsT, aspartate transaminase; ALT, alanine transferase; LDH, 
lactate dehydrogenase; ALP, alkaline phosphatase; γ-GTP, γ-glutamyl transpeptidase; 
Che,  cholinesterase;  TP,  total  protein;  ALB,  albumin;  T-chol,  total  cholesterol; 
TG, triglyceride; Na, sodium; K, potassium; Cl, chloride; CrP, C-reactive protein; 
Glc, glucose; TsH, thyroid stimulating hormone; FT4, free thyroxine; Ab, antibody; 
Ig, immunoglobulin; HBsAg, hepatitis B virus antigen; HCV-Ab, hepatitis C virus 
antibody; HCV-rNA, hepatitis C virus rNA; eBV, epstein-Barr virus; VCA, virus 
capsid antigen; eBNA, epstein-Barr virus nuclear antigen; CMV, cytomegalo virus; 
HeV,  Hepatitis  e  Virus,  ANA;  anti-nuclear  antibody;  M2  Ab,  anti-mitochondrial 
antibody;  P-ANCA,  perinuclear  anti-neutrophil  cytoplasmic  antibody;  C-ANCA, 
cytoplasmic anti-neutrophil cytoplasmic antibody; sIL-2r, serum-soluble interleukin-2 
receptor; DLsT, drug lymphocyte stimulation test HLA, human leukocyte antigen.
lined by hepatocytes that were markedly dilated with loss 
of microvilli and dense deposition of biliary substances 
(Figure 3B and C). A remarkably dilated bile canaliculus was 
observed between two hepatocytes that showed complete 
loss of microvilli and heavy deposition of biliary substances 
(Figure 3B).
The drug-induced hepatitis score8 was 4: “probable.” 
In this patient, symptoms and liver function improved after 
discontinuation of Pabron Gold (Figure 4).
Discussion
A search of the Japanese literature (JMEDPlus) and inter-
national literature (MEDLINE) yielded similar results of 
elevated hepatic transaminases associated with Pabron Gold.9 
The reported liver injury was a mixed type.
The cholestatic jaundice observed in the patient discussed 
can be ascribed to the over-the-counter drug Pabron Gold for 
the following five reasons: (1) the patient had no prior history 
of disease of the liver or biliary tract; (2) no circumstantial International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
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or serological evidence indicated viral hepatitis; (3) a test 
for antimitochondrial antibodies was negative; (4) obstruc-
tion of the common bile duct was improbable because 
ERC was normal and no disorder suggestive of biliary 
tract obstruction was observed following the appearance of 
jaundice; and (5)   jaundice developed 2 weeks after starting 
Pabron Gold, which disappeared promptly after withdrawal 
of the drug.
In the case presented, the toxic metabolites of the com-
ponents of Pabron Gold might have caused injury to the bile 
duct epithelium.
The pathophysiology and mechanisms of DILI are still being 
investigated. They include both hepatocellular and extracellular 
mechanisms. Firstly, the parent drug, or, more frequently, its 
reactive metabolite, causes initial injury through direct cell 
stress, direct mitochondrial inhibition, or specific immune 
reactions such as major histocompatibility complex class II 
presentation of haptenated peptides to T cells. Second, the 
initial injury might induce mitochondrial permeability transition 
(MPT). Direct cell stress causes MPT via the intrinsic pathway 
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Figure 2 Light microscopic findings of liver biopsy. (A) Bile canalicular cholestasis 
findings showing edematous and pigmented hepatocytes around the central vein 
(arrowheads). “C” denotes the central vein. (B) Inflammatory infiltrate is made 
of polynuclear neutrophils and a varying number of eosinophils. Interlobular bile 
duct destruction is present in the portal tract. The arrow indicates destructive 
cholangitis.  “P”  denotes  the  portal  vein.  (C)  He  and  diastase-digested  periodic 
acid-Schiff show intraepithelial neutrophilic infiltration in the interlobular bile duct. 
(D) silver staining shows that basement membrane of the bile duct is preserved, 
but the nuclear arrangement is irregular. (E) Masson’s trichrome staining yields 
no evidence of portal fibrosis. (F) Cytokeratin 7 immunostaining shows positive 
cytoplasmic expression in the bile duct.
Figure 3 Electron microscopic findings. (A) Degenerative bile duct-related epithelial 
cells (arrowhead) are in an apoptotic process, as inferred from the appearance of 
condensed polymorphic and fragmented nuclei. The intercellular space adjacent 
to this degenerative epithelium is remarkably dilated (arrow), implying that bile 
substances are regurgitated from the lumen to the abluminal side. (B) A canal of 
Hering (CoH) with markedly dilated lumen (L) and loss of microvilli is lined by 
two hepatocytes (H1 and H2) and four cholangiocytes (C1–C4) containing deposits 
of electron-dense biliary substances (arrowhead). The intercellular space adjacent 
to epithelium is dilated (arrow). Between the two hepatocytes (H1 and H2) is a 
remarkably dilated bile canaliculus (BC) showing complete loss of microvilli and 
heavy deposition of biliary substances (arrow). (C) This electron micrograph shows 
a pseudo-bile ductule, the lumen of which is lined by six hepatocytes containing bile 
substances. The adjacent bile canaliculus (BC) is dilated with loss of microvilli and 
deposit of bile substances. The arrow indicates deposition of biliary substances.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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that involves activation of intracellular stressor cascades and 
proapoptotic proteins. Third, MPT induces apoptosis or necrosis, 
depending on the availability of adenosine-5′triphosphate. 
Toxic metabolites excreted in bile might cause injury to the 
bile duct epithelium. Cell injury, gut-derived endotoxin, or their 
combination activates Kupffer cells and recruits neutrophils 
into the liver.10,11 In this case, acetaminophen – a component 
of Pabron Gold   – cytochrome P450, family 2, subfamily E, 
polypeptide CYP2E1, plays an important role in the cytochrome 
P450 pathway of acetaminophen metabolism.12 Changes in 
cholangiocyte microvillus architecture are prominent in drug-
induced cholestasis. Large intrahepatic bile ducts express 
CYP2E1. They might be more sensitive to damage by drugs 
metabolized by this enzyme.13
In this case, the authors found that acute drug-induced 
cholangitis – diagnosed from laboratory data and liver biopsy 
findings – was associated with an over-the-counter drug. 
Acute cholangitis has been associated with several agents 
including allopurinol, carbamazepine, hydralazine, and 
sulindac.14–17 These observations suggest that such lesions 
are either specific to or significant for bile duct damage that 
is characteristic of drug-induced hepatic injury. Many such 
changes might reflect bile flow disturbance.
Several recent reports have described a strong genetic 
association between the human leukocyte antigen (HLA) 
allele and susceptibility to drug hypersensitivity. The genetic 
associations might be drug-specific, such as HLA-B1502 with 
carbamazepine-induced Stevens–Johnson syndrome, HLA-
B5701 with abacavir hypersensitivity, and HLA-B5801 with 
allopurinol-induced severe cutaneous adverse reactions.18 The 
high sensitivity and specificity of some markers provides a 
plausible basis for developing tests to identify individuals 
who are at risk for drug hypersensitivity. A patient’s unique 
immune response is likely to play a role in the intensity and 
duration of injury because certain HLA haplotypes have been 
found to be markedly overrepresented in patients who develop 
drug-induced cholestatic hepatitis.19,20 Based on HLA-typing 
results for this patient (Table 1), a genetic association with 
drug-induced hepatitis is unlikely, as described in several 
reports in the aforementioned literature.
The patient’s medical history revealed that she had started 
taking the over-the-counter drug Pabron Gold intermittently, 
for three short durations (3 days each) during the 6 weeks 
before admission, suggesting that the liver damage had 
occurred over a long period. Re-administration of the suspect 
drug during possible drug-induced liver injury can result in 
fatality or severe liver injury. Another survey has revealed 
that most rechallenge liver events occur within 1 month of the 
initial liver injury event.2 Mitochondrial impairment is a key 
mechanism of rechallenge injury, with a possible contribution 
from reactive metabolites.
The patient suffered no bacterial infection. She did not 
complain of fever, cough, localized redness, heat, swelling, or 
pain. The infection started on December 20, when treatment 
with Pabron Gold was started, though it is possible that the 
infection began even earlier. Treatment ended on January 
23, indicating use of the medication for more than 4 weeks. 
A viral infection usually lasts 1–2 weeks. A longer duration 
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Figure 4 Clinical course.
Abbreviations: ALT, alanine transferase; ALP, alkaline phosphatase; T-bil, total bilirubin; γ-GTP, γ-glutamyl transpeptidase; GPT, gutamicpruvate transaminase.International Journal of General Medicine
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might signify bacterial complication. Hospitalization began 
2 weeks after the Pabron Gold treatment. Presumably, the 
underlying disease continued. The high value of C-reactive 
protein suggests a bacterial infection.21 It was inferred that 
these histologic features of acute cholangitis were accompa-
nied with bacterial infection.
During hospitalization, alkaline phosphatase initially 
declined and then started to increase, resulting in a   second 
peak. This is not compatible with DILI, but instead 
  suggests a drug-independent cause.22 On admission, the 
diagnostic procedures performed by endoscopic retrograde 
cholangiopancreatography in this case included a   balloon 
“sweep” of the common duct. Mild cholangitis was 
complicated by alkaline phosphatase.23
“Ductopenia” refers to the absence of interlobular bile 
ducts from within the portal tracts.24 Multiple causes have 
been identified including infection, malignancy, autoimmune 
conditions, and adverse effects of medications.
The diagnostic yield can be increased by   immunostaining with 
CK7, which identifies biliary   elements.   Immunohistochemical 
CK7 staining was used in this case. The analysis facilitated 
the identification of bile ducts in portal tracts with dense 
inflammation where the bile duct was obscured and showed 
well-preserved bile ducts.
Drug-specific genetic screening tests might prevent these 
diseases, which can be catastrophic. The capacity of current 
instruments to assess the causality of DILI might be enhanced 
by a combination of expert opinions. Efforts are underway 
to establish reliable DILI biomarkers.
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